ABVX is a prime acquisition target due to FDA approval progress and ongoing M&A trends.

Allergan. This stock has also been underperforming since the beginning of the year. It is a small biotechnology company, with a market value of only half a billion dollars. They are developing genetically modified T-cell therapies to treat cancer and autoimmune diseases.

I believe it is ready for acquisition by larger pharmaceutical companies now, given that its drugs are on the path to FDA approval. If the pace of mergers and acquisitions continues as it did in the first half of the year, companies like Allergan will attract the attention of major pharmaceutical companies.